Document:

Amendment No. 1 to Amended and Restated Employment Agreement

 Exhibit 10.2 
 AMENDMENT NO. 1 TO 
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 THIS AMENDMENT NO. 1 TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”) made as of
December 17, 2012 (“Effective Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Jean-Jacques Bienaimé (“Employee”). 

 

	1.	This Amendment No. 1 is intended to amend and modify that certain Amended and Restated Employment Agreement by and between the Company and Employee dated January 1,
2009 (the “Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in the Agreement.
Except as expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. 

  

	2.	The first sentence of Section 8 (h) is hereby deleted and replaced in its entirety by the following: 

(h) Mechanics. All Termination Compensation described in Subsections 8(c) (1) above, if any, and the enhanced Termination
Compensation described in Subsections 8(d)(i), 8(d)(ii) and 8(d)(iv) through (vi) above, if any, shall be payable in one lump-sum payment within thirty (30) days of the Employee’s termination date, conditioned on Employee executing the
Company’s standard form severance and release agreement within twenty (20) days of the Employee’s termination, and shall be subject to customary withholding and other applicable payroll processes. If Employee fails to execute and deliver
the Company’s standard form severance and release agreement within twenty (20) days after the Employee’s termination, Employee will have no right to any Termination Compensation under this Agreement. 

 

	3.	This Amendment No. 1 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the date
first written above. 
  

									
	BIOMARIN PHARMACEUTICAL INC.	 		 	EMPLOYEE
					
	By:	 	 /s/ G. Eric Davis
	 		 	By:	 	 /s/ Jean-Jacques Bienaimé

	Name: G. Eric Davis	 		 		 	Jean-Jacques Bienaimé
	Its:      Sr. Vice President & General CounselAmendment No. 1 to Employment Agreement with Jeffrey Ajer

 Exhibit 10.3 
 AMENDMENT NO. 1 TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment”) made as of December 17, 2012 (“Effective
Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Jeffrey R. Ajer (“Employee”). 
  

	1.	This Amendment No. 1 is intended to amend and modify that certain Employment Agreement by and between the Company and Employee dated September 5, 2012 (the
“Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in the Agreement. Except as
expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. 

  

	2.	The defined term “Termination Compensation,” as provided in Section 7(c) of the Agreement, is hereby deleted and replaced in its entirety by the
following definition: 

 Termination Compensation. For purposes of this Agreement, the term
“Termination Compensation” shall mean: (i) one hundred forty percent (140%) of the Employee’s then current annual base salary which shall be payable in a lump sum within forty-five (45) days after separation of employment, conditioned
on Employee executing the Company’s standard form severance and release agreement within twenty (20) days of the Employee’s termination, and shall be subject to customary withholding and other applicable payroll processes. If Employee
fails to execute and deliver the Company’s standard form severance and release agreement within twenty (20) days after the Employee’s termination, Employee will have no right to any Termination Compensation under this Agreement.

  

	3.	This Amendment No. 1 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the date
first written above. 
  

									
	BIOMARIN PHARMACEUTICAL INC.	 		 	EMPLOYEE
					
	By:	 	 /s/ Jean-Jacques Bienaimé
	 		 	By:	 	 /s/ Jeffrey R. Ajer

	Name: Jean-Jacques Bienaimé	 		 		 	Jeffrey R. Ajer
	Its:      Chief Executive OfficerAmendment No. 3 to Employment Agreement with Robert A. Baffi

 Exhibit 10.4 
 AMENDMENT NO. 3 TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the “Amendment”) made as of December 17, 2012 (“Effective
Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Robert A. Baffi, Ph.D (“Employee”). 

 

	1.	This Amendment No. 3 is intended to amend and modify that certain Employment Agreement by and between the Company and Employee dated January 1, 2009 and amended on May
8, 2012 and May 24, 2012 (the “Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in
the Agreement. Except as expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. 

  

	2.	The defined term “Termination Compensation,” as provided in Section 7(c) of the Agreement, is hereby deleted and replaced in its entirety by the
following definition: 

 Termination Compensation. For purposes of this Agreement, the term
“Termination Compensation” shall mean: (i) one hundred fifty percent (150%) of the Employee’s then current annual base salary which shall be payable in a lump sum within forty-five (45) days after separation of employment, conditioned
on Employee executing the Company’s standard form severance and release agreement within twenty (20) days of the Employee’s termination, and shall be subject to customary withholding and other applicable payroll processes. If Employee
fails to execute and deliver the Company’s standard form severance and release agreement within twenty (20) days after the Employee’s termination, Employee will have no right to any Termination Compensation under this Agreement.

  

	3.	This Amendment No. 3 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the date
first written above. 
  

									
	BIOMARIN PHARMACEUTICAL INC.	  		  	EMPLOYEE
					
	By:	 	 /s/ Jean-Jacques Bienaimé
	  		  	By:	 	 /s/ Robert A. Baffi, Ph.D

	Name: Jean-Jacques Bienaimé	  		  		 	Robert A. Baffi, Ph.D
	Its:      Chief Executive OfficerAmendment No. 3 to Employment Agreement with Henry J. Fuchs

 Exhibit 10.5 
 AMENDMENT NO. 3 TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the “Amendment”) made as of December 17, 2012 (“Effective
Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Henry J. Fuchs (“Employee”). 
  

	1.	This Amendment No. 3 is intended to amend and modify that certain Employment Agreement by and between the Company and Employee dated March 2, 2009 and amended on May 8,
2012 and May 24, 2012 (the “Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in
the Agreement. Except as expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. 

  

	2.	The defined term “Termination Compensation,” as provided in Section 7(c) of the Agreement, is hereby deleted and replaced in its entirety by the
following definition: 

 Termination Compensation. For purposes of this Agreement, the term
“Termination Compensation” shall mean: (i) one hundred fifty percent (150%) of the Employee’s then current annual base salary which shall be payable in a lump sum within forty-five (45) days after separation of employment, conditioned
on Employee executing the Company’s standard form severance and release agreement within twenty (20) days of the Employee’s termination, and shall be subject to customary withholding and other applicable payroll processes. If Employee
fails to execute and deliver the Company’s standard form severance and release agreement within twenty (20) days after the Employee’s termination, Employee will have no right to any Termination Compensation under this Agreement.

  

	3.	This Amendment No. 3 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the date
first written above. 
  

									
	BIOMARIN PHARMACEUTICAL INC.	  		  	EMPLOYEE
					
	By:	 	 /s/ Jean-Jacques Bienaimé
	  		  	By:	 	 /s/ Henry J. Fuchs

	Name: Jean-Jacques Bienaimé	  		  		 	Henry J. Fuchs
	Its:      Chief Executive OfficerAmendment No. 2 to Employment Agreement with G. Eric Davis

 Exhibit 10.6 
 AMENDMENT NO. 2 TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment”) made as of December 17, 2012 (“Effective
Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and G. Eric Davis (“Employee”). 
  

	1.	This Amendment No. 2 is intended to amend and modify that certain Employment Agreement by and between the Company and Employee dated January 1, 2009 and amended on May
8, 2012 (the “Agreement”). The Agreement, together with this Amendment, shall constitute a single agreement. Capitalized terms not otherwise defined in this Amendment shall have the meaning ascribed to such terms in the Agreement.
Except as expressly modified by this Amendment, the Agreement shall remaining full force and effect according to its terms. 

  

	2.	The defined term “Termination Compensation,” as provided in Section 7(c) of the Agreement, is hereby deleted and replaced in its entirety by the
following definition: 

 Termination Compensation. For purposes of this Agreement, the term
“Termination Compensation” shall mean: (i) one hundred forty percent (140%) of the Employee’s then current annual base salary which shall be payable in a lump sum within forty-five (45) days after separation of employment, conditioned
on Employee executing the Company’s standard form severance and release agreement within twenty (20) days of the Employee’s termination, and shall be subject to customary withholding and other applicable payroll processes. If Employee
fails to execute and deliver the Company’s standard form severance and release agreement within twenty (20) days after the Employee’s termination, Employee will have no right to any Termination Compensation under this Agreement.

  

	3.	This Amendment No. 2 may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment as of the date
first written above. 
  

									
	BIOMARIN PHARMACEUTICAL INC.	  		  	EMPLOYEE
					
	By:	 	 /s/ Jean-Jacques Bienaimé
	  		  	By:	 	 /s/ G. Eric Davis

	Name: Jean-Jacques Bienaimé	  		  		 	G. Eric Davis
	Its:      Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]